Roche to increase payroll in Switzerland by 1.4 percent

Basel, 05 December 2012

Roche is increasing the payroll for its workforce of over 11,000 in Switzerland by 1.4 percent with effect from 1 April 2013. This latest increase acknowledges the workforce’s outstanding dedication in a challenging market environment in Europe and Switzerland. It also takes into account the salaries and wages for comparable employment, and increases in the cost of living.

Over recent weeks the company has been negotiating the 2013 payroll increase with the Roche Switzerland Employees’ Association and the Roche Basel Works Council. The result announced today was endorsed by all parties following fair, focused and constructive negotiations.

The 1.4 percent payroll increase will be used to calculate the total amount available to managers for distribution to their staff in the form of individual, performance-based salary increases as of 1 April 2013.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: